Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer

(REAL Trial)

Recruiting in Palo Alto (17 mi)

+47 other locations

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: Novartis Pharmaceuticals

No Placebo Group

Prior Safety Data

Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?

This study will evaluate whether patients who are intolerant and discontinue anastrozole due to grade 2-3 arthralgia-myalgia have a decrease in rheumatological symptoms while taking letrozole

Eligibility Criteria

Inclusion Criteria

Age ≥ 50 y and amenorrheic for 12 or more months.

Age ≥ 50 y and amenorrheic for 3 or more months after receiving adjuvant chemotherapy.

Age < 50 y and amenorrheic for 12 or more months.

Treatment Details

Interventions

• Letrozole (Aromatase Inhibitor)

Participant Groups

Group I: Letrozole Experimental Treatment 1 Intervention

Participants received 2.5 milligram (mg) of Letrozole tablets orally once daily (QD) for a period of 24 weeks.

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Cooper University Hospital Voorhees, NJ

Central Utah Clinic American Fork, UT

Suburban Hospital Cancer Program Bethesda, MD

Tenessee Oncology Nashville, TN

More Trial Locations

Who Is Running the Clinical Trial?

Novartis Pharmaceuticals Lead Sponsor

References